Modified vacuum-assisted closure (EndoVAC) therapy for treatment of pharyngocutaneous fistula: Case series and a review of the literature.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
08 2021
Historique:
revised: 23 01 2021
received: 08 12 2020
accepted: 16 03 2021
pubmed: 9 4 2021
medline: 11 8 2021
entrez: 8 4 2021
Statut: ppublish

Résumé

Pharyngocutaneous fistula is a potential life-threatening complication following head and neck surgery. There is only limited evidence about the efficacy of vacuum-assisted closure (VAC) therapy and endoscopic vacuum-assisted closure (EndoVAC) therapy for the treatment of pharyngocutaneous fistulas. In this article, we report on a consecutive case series of six male patients with pharyngocutaneous fistula treated with a modified outside-in EndoVAC technique. We also present a review of the current related literature. EndoVAC therapy alone was successful in five of the six patients (83.3%) with a median duration of EndoVAC therapy of 18.5 days (range: 7 to 32 days) and a median number of EndoVAC sponge changes of 4 (range: 1 to 9 changes). One patient needed additional reconstructive surgery after prior radiochemotherapy and jejunal transfer. No treatment-related complications were observed. EndoVAC therapy is an easy-to-perform, safe procedure for the treatment of pharyngocutaneous fistulae.

Sections du résumé

BACKGROUND
Pharyngocutaneous fistula is a potential life-threatening complication following head and neck surgery. There is only limited evidence about the efficacy of vacuum-assisted closure (VAC) therapy and endoscopic vacuum-assisted closure (EndoVAC) therapy for the treatment of pharyngocutaneous fistulas.
METHODS
In this article, we report on a consecutive case series of six male patients with pharyngocutaneous fistula treated with a modified outside-in EndoVAC technique. We also present a review of the current related literature.
RESULTS
EndoVAC therapy alone was successful in five of the six patients (83.3%) with a median duration of EndoVAC therapy of 18.5 days (range: 7 to 32 days) and a median number of EndoVAC sponge changes of 4 (range: 1 to 9 changes). One patient needed additional reconstructive surgery after prior radiochemotherapy and jejunal transfer. No treatment-related complications were observed.
CONCLUSION
EndoVAC therapy is an easy-to-perform, safe procedure for the treatment of pharyngocutaneous fistulae.

Identifiants

pubmed: 33830587
doi: 10.1002/hed.26684
pmc: PMC9542148
doi:

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2377-2384

Informations de copyright

© 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.

Références

Laryngorhinootologie. 2020 Apr;99(4):229-236
pubmed: 32079025
JAMA Facial Plast Surg. 2014 Mar-Apr;16(2):120-6
pubmed: 24357046
Anaesth Intensive Care. 2002 Oct;30(5):633-40
pubmed: 12413266
Eur Arch Otorhinolaryngol. 2006 Dec;263(12):1127-30
pubmed: 17021782
Eur Arch Otorhinolaryngol. 2020 May;277(5):1437-1448
pubmed: 31982945
JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):143-9
pubmed: 24370595
Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):78-84
pubmed: 14515083
Acta Otorhinolaryngol Ital. 2015 Dec;35(6):400-5
pubmed: 26900245
Laryngoscope. 2014 May;124(5):1150-63
pubmed: 24122657
Head Neck. 2015 Sep;37(9):1233-8
pubmed: 24801433
Ann Thorac Surg. 2010 Nov;90(5):1674-81
pubmed: 20971288
J Otolaryngol. 1998 Jun;27(3):136-40
pubmed: 9664242
Ann Otol Rhinol Laryngol. 1978 Mar-Apr;87(2 Pt 1):159-62
pubmed: 417655
HNO. 2019 Jun;67(Suppl 2):77-79
pubmed: 31053941
J Laryngol Otol. 2018 May;132(5):380-384
pubmed: 29444718
Laryngoscope. 1979 Feb;89(2 Pt 1):250-60
pubmed: 423664
Head Neck. 2021 Aug;43(8):2377-2384
pubmed: 33830587
Surg Endosc. 2008 Aug;22(8):1818-25
pubmed: 18095024
Endoscopy. 2013 Jun;45(6):433-8
pubmed: 23733727
Endosc Int Open. 2015 Dec;3(6):E547-51
pubmed: 26716109
Endoscopy. 2012;44 Suppl 2 UCTN:E49-50
pubmed: 22396274
Eur Arch Otorhinolaryngol. 2019 Jan;276(1):143-151
pubmed: 30426230
ANZ J Surg. 2018 Apr;88(4):E257-E263
pubmed: 27860126
Surg Obes Relat Dis. 2016 Aug;12(7):1278-1285
pubmed: 27178614
Endoscopy. 2010 Sep;42(9):693-8
pubmed: 20806153
Clin Otolaryngol. 2018 Feb;43(1):109-116
pubmed: 28544550
Zentralbl Chir. 2004 May;129 Suppl 1:S7-11
pubmed: 15168274
Am J Clin Dermatol. 2005;6(3):185-94
pubmed: 15943495
Eur Arch Otorhinolaryngol. 2008 Aug;265(8):929-36
pubmed: 18247039
Otolaryngol Head Neck Surg. 2012 Mar;146(3):395-402
pubmed: 22166968
World J Gastroenterol. 2014 Jun 28;20(24):7767-76
pubmed: 24976714
Laryngoscope. 2019 Mar;129(3):671-683
pubmed: 30134500

Auteurs

Teresa Bernadette Steinbichler (TB)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Dolores Wolfram (D)

Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Annette Runge (A)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Roland Hartl (R)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Daniel Dejaco (D)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Tina Rauchenwald (T)

Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Claus Pototschnig (C)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Herbert Riechelmann (H)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Volker Hans Schartinger (VH)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH